Themis Medicare Ltd

₹ 103 -1.04%

15 Jun - close price

themismedicare.com BSE: 530199 NSE: THEMISMED

About

Incorporated in 1969, Themis Medicare manufactures Formulation and API pharmaceutical products^[1]

Key Points

Business Overview:^[1]
TML is in manufacturing antiseptics, anti-tuberculosis, anti-malarial, anti-cholesterol and pain management drugs.

Website BSE NSE

Market Cap ₹ 948 Cr.
Current Price ₹ 103
High / Low ₹ 148 / 65.0
Stock P/E 574
Book Value ₹ 43.3
Dividend Yield 0.49 %
ROCE 2.74 %
ROE 0.41 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company has been maintaining a healthy dividend payout of 143%

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of 8.21% over past five years.
Company has a low return on equity of 6.53% over last 3 years.
Earnings include an other income of Rs.22.5 Cr.
Company has high debtors of 190 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	80.10	96.65	104.78	82.51	97.82	122.99	117.01	93.81	71.70	97.58	77.99	90.13	76.53
	69.62	74.91	92.37	74.46	88.53	93.81	99.88	87.84	79.40	107.80	81.09	80.33	72.77
Operating Profit	10.48	21.74	12.41	8.05	9.29	29.18	17.13	5.97	-7.70	-10.22	-3.10	9.80	3.76
OPM %	13.08%	22.49%	11.84%	9.76%	9.50%	23.73%	14.64%	6.36%	-10.74%	-10.47%	-3.97%	10.87%	4.91%
	5.32	6.29	6.66	5.94	4.67	6.93	5.56	1.02	1.55	1.18	4.98	5.93	10.60
Interest	2.71	2.49	2.04	2.68	2.16	2.36	2.44	2.79	2.45	2.47	2.76	2.75	2.70
Depreciation	2.80	3.03	3.07	3.10	3.06	2.41	2.45	2.54	2.53	2.55	2.57	2.59	2.60
Profit before tax	10.29	22.51	13.96	8.21	8.74	31.34	17.80	1.66	-11.13	-14.06	-3.45	10.39	9.06
Tax %	18.37%	19.19%	18.91%	10.35%	24.14%	21.25%	19.66%	68.67%	-13.12%	1.14%	4.64%	2.79%	1.88%
	8.41	18.19	11.32	7.37	6.64	24.68	14.29	0.52	-9.66	-14.22	-3.62	10.09	8.89
EPS in Rs	0.91	1.98	1.23	0.80	0.72	2.68	1.55	0.06	-1.05	-1.54	-0.39	1.10	0.97
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	202	232	217	210	184	202	231	395	354	382	406	342
	184	194	184	184	181	166	181	299	287	330	356	342
Operating Profit	18	38	33	25	2	36	49	96	67	52	49	0
OPM %	9%	16%	15%	12%	1%	18%	21%	24%	19%	13%	12%	0%
	13	3	4	6	5	12	13	18	25	24	11	23
Interest	15	12	12	12	12	13	13	9	10	9	10	11
Depreciation	11	12	7	7	8	8	9	9	10	12	10	10
Profit before tax	5	17	18	11	-13	27	41	95	73	53	40	2
Tax %	-20%	11%	9%	1%	-15%	8%	14%	23%	22%	19%	25%	40%
	6	16	16	11	-11	25	36	73	57	44	30	1
EPS in Rs	0.73	1.91	1.77	1.23	-1.17	2.70	3.88	7.92	6.18	4.73	3.24	0.12
Dividend Payout %	25%	9%	0%	0%	0%	6%	11%	6%	8%	11%	15%	404%

Compounded Sales Growth
10 Years:	4%
5 Years:	8%
3 Years:	-1%
TTM:	-16%

Compounded Profit Growth
10 Years:	-20%
5 Years:	-46%
3 Years:	-69%
TTM:	-94%

Stock Price CAGR
10 Years:	6%
5 Years:	7%
3 Years:	-10%
1 Year:	-26%

Return on Equity
10 Years:	11%
5 Years:	12%
3 Years:	7%
Last Year:	0%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	8	9	9	9	9	9	9	9	9	9	9	9
Reserves	51	66	143	160	149	174	209	278	330	368	393	389
	140	128	82	80	82	100	87	80	92	96	83	100
	77	73	54	56	74	67	65	61	82	93	102	99
Total Liabilities	277	275	289	305	314	350	371	428	514	566	588	598
	122	117	124	126	123	116	133	144	162	168	172	167
CWIP	4	6	9	2	2	8	2	3	3	3	3	2
Investments	5	6	23	24	27	35	45	56	70	89	95	109
	146	146	133	153	162	191	191	225	279	307	318	320
Total Assets	277	275	289	305	314	350	371	428	514	566	588	598

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	19	26	-2	8	11	0	57	34	16	22	35	-3
	-6	-7	-4	-0	-4	-5	-16	-16	-24	-16	-12	-3
	-18	-13	5	-9	-10	7	-26	-18	0	-9	-26	4
Net Cash Flow	-5	5	-0	-1	-3	2	16	1	-8	-3	-3	-2
Free Cash Flow	13	18	-7	5	5	-5	39	15	-13	4	21	-8
CFO/OP	101%	73%	-5%	29%	490%	2%	115%	55%	48%	60%	93%	782%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	82	75	81	120	145	186	123	93	149	170	159	190
Inventory Days	246	243	250	253	287	315	272	150	213	188	233	229
Days Payable	237	145	163	156	187	171	143	79	123	126	142	143
Cash Conversion Cycle	91	172	168	216	244	330	251	164	239	232	250	275
Working Capital Days	-20	-17	-16	19	-1	37	51	72	110	116	121	138
ROCE %	9%	15%	13%	10%	-1%	15%	18%	30%	20%	14%	10%	3%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Number of Permanent Employees
Count ・Standalone data

x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	xxx	x,xxx	xxx	x,xxx	x,xxx
xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx
		xx.xx	x.xx						xx.xx	xx.xx
		xx,xxx,xxx	xx,xxx,xxx						xx,xxx,xxx	xx,xxx,xxx
									xxx

Please log in to see hidden values.

R&D Expenditure (Total)
INR Lakhs

Production Volumes (Bulk Drugs)
Metric Tonnes

Production Volumes (Formulations)
Units

Number of Formulations Dossiers Filled (ROW)
Count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	67.16%	67.16%	67.16%	67.15%	67.15%	67.15%	67.15%	67.15%	67.15%	67.15%	67.10%	67.10%
	0.04%	0.05%	0.01%	0.03%	0.05%	0.10%	0.10%	0.14%	0.09%	0.06%	0.05%	0.11%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
	32.80%	32.77%	32.82%	32.81%	32.79%	32.74%	32.75%	32.70%	32.75%	32.77%	32.84%	32.78%
No. of Shareholders	6,007	6,970	11,244	11,295	11,322	14,270	17,773	17,889	19,335	22,490	22,576	21,818

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	66.99%	67.32%	67.32%	67.27%	67.26%	67.18%	67.16%	67.15%	67.15%	67.10%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.03%	0.14%	0.11%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
	33.00%	32.67%	32.67%	32.72%	32.73%	32.81%	32.78%	32.81%	32.70%	32.78%
No. of Shareholders	4,215	4,039	4,032	3,902	5,858	5,891	5,927	11,295	17,889	21,818

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

May 2026

Transcript

AI Summary
PPT
Feb 2026

Transcript

AI Summary
PPT
Nov 2025

Transcript

AI Summary
PPT
Aug 2025

Transcript

AI Summary
PPT
May 2025

Transcript

AI Summary
PPT
Feb 2025

Transcript

AI Summary
PPT
Oct 2024

Transcript

AI Summary
PPT
Jul 2024

Transcript

AI Summary
PPT
May 2024

Transcript

AI Summary
PPT
Feb 2024

Transcript

AI Summary
PPT
Nov 2023
Transcript PPT
Aug 2023

Transcript

AI Summary
PPT
May 2023
Transcript PPT
Feb 2023
Transcript
PPT
REC
Feb 2023
Transcript PPT
Nov 2022
Transcript PPT